ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,768.50
0.43%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alzamend Neuro Inc (ALZN)

  7. Alzamend Neuro Inc (ALZN) News

Alzamend Neuro (ALZN)

Alzamend Neuro Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALZN
DateTimeSourceHeadlineSymbolCompany
31/05/202421:59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
22/05/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
22/05/202413:00Business WireAlzamend Neuro Announces Favorable Decision from Nasdaq Hearings PanelNASDAQ:ALZNAlzamend Neuro Inc
16/05/202421:30Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
14/05/202413:00Business WireAlzamend Neuro Announces Initial Closing of Private PlacementNASDAQ:ALZNAlzamend Neuro Inc
13/05/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
10/05/202422:06Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
10/05/202421:30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALZNAlzamend Neuro Inc
10/05/202411:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
09/05/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
09/05/202421:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
09/05/202413:00Business WireAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionNASDAQ:ALZNAlzamend Neuro Inc
07/05/202421:31Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
07/05/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
07/05/202413:00Business WireAlzamend Neuro Announces Termination of At-the-Market Equity Offering ProgramNASDAQ:ALZNAlzamend Neuro Inc
07/03/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
02/02/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
05/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
15/12/202321:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
11/12/202313:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
20/11/202313:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
16/11/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
16/11/202313:00Business WireAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNASDAQ:ALZNAlzamend Neuro Inc
13/11/202313:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
30/10/202320:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
30/10/202312:00Business WireAlzamend Neuro Announces Reverse Stock SplitNASDAQ:ALZNAlzamend Neuro Inc
23/10/202313:00Business WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
02/10/202313:00Business WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
29/09/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
26/09/202323:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
 Showing the most relevant articles for your search:NASDAQ:ALZN

Your Recent History

COIN
LIGHTTUSD
COIN
OOKIGBP
Ooki Token
MRTX
DIDBTC
Decentralized ID
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved